Study Multicentre Evaluating the Effectiveness and Toxicity Sorafenib (Nexavar®) in Adult Patients With Uveal Melanoma and Metastatic Dissemination

Summary

The objective of the study is to determine the efficacy and toxicity of sorafenib in metastatic uveal melanoma. The main objective is to determine the non-tumor progression rate 24 weeks after initiation of treatment with sorafenib at a dose of 800 mg / day

Timeline

Start

2012-02

Primary completion

2015-01-13

Completion

2015-01-13

Publications

• Results Mouriaux F, Servois V, Parienti JJ, Lesimple T, Thyss A, Dutriaux C, Neidhart-Berard EM, Penel N, Delcambre C, Peyro Saint Paul L, Pham AD, Heutte N, Piperno-Neumann S, Joly F. Sorafenib in metastatic uveal melanoma: efficacy, toxicity and health-related quality of life in a multicentre phase II study. Br J Cancer. 2016 Jun 28;115(1):20-4. doi: 10.1038/bjc.2016.119. Epub 2016 Jun 2.

Drugs

Indications